Product Information
NYSTATIN-TRIAMCINOLONE CREAM is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $0.2893 per GM under NDC 45802088014. Its NADAC has been published 456 times since Jan 10, 2018.
FDA first approved this application on Aug 14, 2017. Its Orange Book therapeutic-equivalence code is AT.
Strength
100000; 1 [USP'U]/g; mg/g
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802088014
Classification
Generic
Dosage Form
CREAM
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
NYSTATIN; TRIAMCINOLONE ACETONIDEApproval Type
Generic (ANDA)
FDA Application
ANDA208479FDA Approved
8/14/2017
TE Code
AT
On Market Since
11/27/2017
Pharmacological Classes
Price Statistics
The NADAC for NYSTATIN-TRIAMCINOLONE CREAM has been published 456 times since Jan 10, 2018, and over the history we have for it it has declined 89.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2893 per GM |
|---|---|
| All-time high | $2.8754 (Jan 10, 2018) |
| All-time low | $0.2522 (Jan 18, 2023) |
| 52-week high | $0.3167 |
| 52-week low | $0.2684 |
| Median price | $0.5433 |
| Average price | $0.6896 |
| Largest weekly change | +60.8% (May 22, 2024) |
| Weeks tracked | 456 |
| Tracking since | Jan 10, 2018 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 34% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
nystatin, triamcinolone acetonide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NYSTATIN-TRIAMCINOLONE CREAM?
The current National Average Drug Acquisition Cost (NADAC) for NYSTATIN-TRIAMCINOLONE CREAM, manufactured by Padagis Israel Pharmaceuticals Ltd, is $0.2893 per GM (NDC 45802088014), effective Sep 30, 2026.
How has the price of NYSTATIN-TRIAMCINOLONE CREAM changed over time?
Over the history we have for it, the NADAC for NYSTATIN-TRIAMCINOLONE CREAM has declined 89.9%. It has been tracked across 456 weekly CMS publications since Jan 10, 2018.
What are the highest and lowest recorded NADAC prices for NYSTATIN-TRIAMCINOLONE CREAM?
Since Jan 10, 2018, the NADAC for NYSTATIN-TRIAMCINOLONE CREAM has ranged from a low of $0.2522 (Jan 18, 2023) to a high of $2.8754 (Jan 10, 2018), with a median of $0.5433 per GM.
Are there cheaper alternatives to NYSTATIN-TRIAMCINOLONE CREAM?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, NYSTATIN-TRIAMCINOLONE CREAM, is $0.1916 per GM — about 34% below NYSTATIN-TRIAMCINOLONE CREAM.
Who manufactures NYSTATIN-TRIAMCINOLONE CREAM?
NYSTATIN-TRIAMCINOLONE CREAM (NDC 45802088014) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.